Johnson & Johnson annual ebitda
2009
2010
2011
2012
2013
2014
2022
2023
2024
2025
Johnson & Johnson EBITDA Growth & History (JNJ)
Johnson & Johnson's calculated EBITDA was $41.05B for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-28 | $41.05B | $16.27B | +65.67% |
| 2024 | 2024-12-29 | $24.78B | $1.46B | +6.27% |
| 2023 | 2023-12-31 | $23.32B | −$3.29B | −12.35% |
| 2022 | 2023-01-01 | $26.61B | — | — |
| 2014 | 2014-12-28 | $25.48B | $4.97B | +24.22% |
| 2013 | 2013-12-29 | $20.52B | $1.90B | +10.18% |
| 2012 | 2012-12-30 | $18.62B | $1.70B | +10.03% |
| 2011 | 2012-01-01 | $16.92B | −$3.72B | −18.00% |
| 2010 | 2011-01-02 | $20.64B | $1.28B | +6.63% |
| 2009 | 2010-01-03 | $19.36B | — | — |
Johnson & Johnson quarterly ebitda
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $8.99B | $245.0M | +2.80% |
| Q1 2026 | 2026-03-29 | $8.27B | — | — |
| Q4 2025 | 2025-12-28 | $7.19B | — | — |
| Q3 2025 | 2025-09-28 | $9.52B | — | — |
| Q2 2025 | 2025-06-29 | $8.74B | — | — |
| Q1 2015 | 2015-03-29 | $6.72B | $58.0M | +0.87% |
| Q4 2014 | 2014-12-28 | $4.00B | −$138.0M | −3.33% |
| Q3 2014 | 2014-09-28 | $7.99B | $3.14B | +64.85% |
| Q2 2014 | 2014-06-29 | $6.83B | $817.0M | +13.59% |
| Q1 2014 | 2014-03-30 | $6.66B | $1.15B | +20.77% |
| Q4 2013 | 2013-12-29 | $4.14B | −$239.0M | −5.46% |
| Q3 2013 | 2013-09-29 | $4.85B | $18.0M | +0.37% |
| Q2 2013 | 2013-06-30 | $6.01B | $2.50B | +71.27% |
| Q1 2013 | 2013-03-31 | $5.52B | −$385.0M | −6.52% |
| Q4 2012 | 2012-12-30 | $4.38B | $2.68B | +158.35% |
| Q3 2012 | 2012-09-30 | $4.83B | −$602.0M | −11.08% |
| Q2 2012 | 2012-07-01 | $3.51B | −$806.0M | −18.68% |
| Q1 2012 | 2012-04-01 | $5.90B | $422.0M | +7.70% |
| Q4 2011 | 2012-01-01 | $1.70B | — | — |
| Q3 2011 | 2011-10-02 | $5.43B | $346.0M | +6.80% |
| Q2 2011 | 2011-07-03 | $4.32B | −$774.0M | −15.21% |
| Q1 2011 | 2011-04-03 | $5.48B | — | — |
| Q3 2010 | 2010-10-03 | $5.09B | — | — |
| Q2 2010 | 2010-07-04 | $5.09B | — | — |
Johnson & Johnson ebitda trends
Between the periods ended 2010-01-03 and 2025-12-28, Johnson & Johnson's ebitda increased from $19.36B to $41.05B, a change of $21.70B. The latest reported quarter, Q2 2026, shows $8.99B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
